General MedicationsTOPICALGeneric
ESKATA
HYDROGEN PEROXIDE
Standard Dose
40%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview ESKATA is listed in Drugs@FDA under application 209305 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient HYDROGEN PEROXIDE Form and strength SOLUTION;TOPICAL - 40% Sponsor ACLARIS Submission history Latest submission status date: 2019-02-07 00:00:00.
Structured Monograph
Clinical summary
Approval overview ESKATA is listed in Drugs@FDA under application 209305 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient HYDROGEN PEROXIDE Form and strength SOLUTION;TOPICAL - 40% Sponsor ACLARIS Submission history Latest submission status date: 2019-02-07 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.